01Purpose and principlesWhat the treatment does and how it fits into care.
Metastatic disease changes treatment intent but not the need for diagnostic precision. A solitary bone or liver lesion can be benign or a different cancer; a safe biopsy can confirm breast origin and current receptors. Systemic therapy selection then balances phenotype, previous treatment, interval, organ function, disease tempo and patient goals. Sequential treatment often preserves quality of life better than maximum-intensity combination therapy when there is no immediate organ threat.
Supportive care anticipates emergencies and daily burdens. Bone metastases cause pain, fracture, hypercalcaemia and cord compression; liver and lung disease can produce rapid organ compromise; chest-wall tumour can bleed, smell, exude or become infected. Palliative care provides symptom expertise and psychological support while active oncology continues. Treatment success is measured in comfort, function and time aligned with the patient’s priorities as well as scan response.
Key points
- Metastatic breast cancer has spread beyond breast and regional nodes, commonly to bone, liver, lung or brain; treatment aims to prolong life, control disease and preserve quality of life.
- Biopsy an accessible metastatic site when safe if it will confirm recurrence, exclude another diagnosis or reassess ER and HER2 in a way that changes management.
- For initial distant diagnosis and staging, use CECT of chest, abdomen and pelvis or FDG PET-CT under NICE 2026; choose according to the clinical question, tumour uptake, access and patient preference. Consider the same effective modality for response assessment.
- Choose advanced-disease systemic treatment from current HR/HER2, prior treatment and response, disease tempo, fitness, preferences and commissioning. Eligible HR-positive, HER2-negative disease has endocrine-based NICE options, including specified combinations; liver metastasis alone does not dictate chemotherapy.
- New neurological signs of spinal cord compression require immediate specialist contact and 16 mg dexamethasone orally or equivalent parenterally as soon as possible, then daily while awaiting surgery or radiotherapy.
- Symptom control runs alongside disease treatment: analgesia, antiemesis, bowel care, bone-targeted treatment, single-fraction radiotherapy for painful bone disease, wound care and specialist palliative support.
02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.
Persistent focal or night pain, vertebral tenderness, fracture, hypercalcaemia or neurological change suggests skeletal complications requiring site-specific assessment.
Breathlessness, hypoxia, jaundice, ascites, rapidly abnormal liver tests or poor intake can indicate organ-threatening disease needing a faster response.
New focal deficit, seizure, persistent headache, vomiting, cognitive change or imbalance prompts urgent neurological assessment and brain imaging.
Fungating chest-wall tumour can cause pain, bleeding, malodour, exudate and infection and needs coordinated breast, wound and palliative care.
03Assessment before treatmentTests and checks that guide safe selection.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
Biopsy of accessible recurrenceFirst step - Why
- Confirm metastatic breast carcinoma and reassess ER and HER2 when results could alter treatment.
- Interpretation and limitations
- Compare with the primary but use the current representative specimen when reliable; discordance may reflect evolution or heterogeneity.
- 02
CECT or FDG PET-CT for distant staging - Why
- Assess the presence and extent of distant metastases at initial diagnosis and establish an effective baseline for later response assessment.
- Interpretation and limitations
- NICE June 2026 recommends CECT of chest, abdomen and pelvis from the supraclavicular fossae to the proximal femurs, or FDG PET-CT. Consider the indication, potentially greater PET sensitivity, lower FDG uptake in some lobular and low-grade cancers, availability without treatment delay and the person’s preferences. If uncertainty remains or further characterisation is needed, choose additional CECT, FDG PET-CT, MRI, ultrasound, bone scintigraphy or radiography to answer that specific question. Consider using the same effective modality for follow-up; assess clinical deterioration before the next planned scan.
- 03
Bone imaging - Why
- Map painful or structural skeletal disease and identify fracture or cord-compression risk.
- Interpretation and limitations
- For initial distant staging use the CECT or FDG PET-CT pathway, adding targeted imaging when uncertainty or a specific skeletal question remains. Bone scintigraphy may help selected diagnostic questions but NICE advises against using it to monitor treatment response. Focal instability, a threatened fracture and suspected cord compression each need their own urgent assessment rather than simply another routine staging scan.
- 04
Whole-spine MRI for suspected MSCC - Why
- Locate cord or cauda equina compression and guide urgent surgery or radiotherapy.
- Interpretation and limitations
- With suspected MSCC, obtain MRI as soon as possible and always within 24 hours, at the local hospital or a suitable centre with direct access; transfer for MRI only if local imaging is impossible. Contact the specialist pathway immediately and do not let routine outpatient staging delay protection of neurological function.
04Treatment approachPreparation, options, escalation and aftercare.
01Worked case: first metastatic recurrenceConfirm biology and choose treatment tempoFirst stepA postmenopausal patient who completed adjuvant endocrine treatment six years earlier has new HR-positive, HER2-negative liver metastases, preserved organ function, mild symptoms and no previous systemic treatment for advanced disease.+
- 1In this illustrative case, a postmenopausal patient completed adjuvant endocrine treatment six years earlier and has received no systemic treatment for advanced disease. She now has mild symptoms, liver lesions, preserved liver function and good performance. CECT of the chest, abdomen and pelvis defines the metastatic burden; there is no immediate organ-threatening deterioration.
- 2A safely accessible liver lesion is biopsied because confirming the diagnosis and current receptors will change care. Histology confirms metastatic breast carcinoma that remains HR-positive and HER2-negative. The team reviews prior endocrine exposure, comorbidity, interactions and the patient’s preference for disease control with an acceptable treatment burden.
- 3First lineThe oncology team selects an eligible endocrine-based combination after reviewing the current NICE appraisal and its exact access conditions. CG81 lists an aromatase inhibitor with abemaciclib, ribociclib or palbociclib, which are CDK4/6 inhibitors, as first-line endocrine options for some people with HR-positive, HER2-negative advanced cancer. A person without previous endocrine treatment is assessed against the first-line options; previous endocrine exposure has separate specified pathways requiring precise appraisal matching. In this illustrative case, prior treatment, the long treatment-free interval, preserved organ function and preference are considered together. Liver metastases alone do not demand immediate combination chemotherapy.
- 4Symptom and psychological support are started alongside disease-directed treatment. At the agreed early review, discomfort is reduced, organ function remains preserved and treatment toxicity is acceptable. Palliative-care support is offered according to her needs while active anticancer care continues.
- 5Repeat CECT using the effective baseline modality shows reduced measurable disease. The patient and team review that result together and continue the selected treatment with a documented toxicity, symptom and imaging review plan. New deterioration would trigger assessment before the routine scan date rather than being dismissed because the first response was favourable.
02Cord-compression emergencyPreserve neurological functionA person with known bone metastases develops severe thoracic back pain, leg weakness and new urinary retention.+
- 1Contact the MSCC coordinator or acute oncology service immediately and institute safe positioning and transfer according to neurological and spinal stability assessment.
- 2Give dexamethasone 16 mg orally or equivalent parenterally as soon as possible for neurological signs, monitor glucose and give proton-pump-inhibitor protection.
- 3Arrange MRI as soon as possible and always within 24 hours, with urgent specialist spinal surgical and clinical oncology review. Use local direct-access MRI where possible; do not wait for routine clinic or move the patient solely to obtain tertiary imaging if an appropriate local scan is available.
- 4DefinitiveContinue dexamethasone 16 mg daily while awaiting surgery or radiotherapy. Begin gradual reduction after surgery or at the start of radiotherapy under the specialist plan; do not wait until the whole radiotherapy course ends. If dexamethasone was given before imaging and both spinal metastases and MSCC are ruled out, discontinue it. Reassess neurological function, glucose, infection and steroid toxicity while definitive treatment proceeds.
03Fungating wound pathwayControl symptoms without traumatic dressingsProgressive chest-wall tumour produces heavy exudate, malodour, pain and intermittent bleeding.+
- 1Ask the breast multidisciplinary, wound and palliative-care teams to assess tumour control, infection, bleeding risk, pain and caregiver burden together.
- 2Choose a non-adherent absorbent dressing, protect surrounding skin and use topical or systemic measures only for defined odour, bleeding or infection indications.
- 3Consider systemic therapy or palliative radiotherapy when likely to reduce local burden within the patient’s goals and fitness.
- 4Provide anticipatory supplies, an urgent major-bleeding plan and regular review of pain, exudate, odour and psychological distress.
05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.
Dexamethasone: Glenmark 4 mg soluble tablets for neurological MSCC
NICE NG234: give 16 mg orally, or equivalent parenterally, as soon as possible for neurological symptoms or signs of MSCC, then 16 mg daily while awaiting surgery or radiotherapy. For this selected oral product, 16 mg is four 4 mg tablets dissolved in water (approximately 50 mL minimum) and drunk immediately. Do not subdivide tablets or the prepared solution. Reduce gradually after surgery or at radiotherapy start using an appropriate lower strength or formulation under the specialist plan; no fixed taper is implied.Do not delay the MSCC coordinator, MRI or definitive care. Monitor glucose and provide proton-pump-inhibitor protection. If given before imaging, stop when BOTH spinal metastases and MSCC are ruled out. Check hypersensitivity, untreated systemic infection, systemic fungal infection, peptic ulcer, live-vaccine and relevant parasitic-infection risks; the SmPC recognises that life-saving emergency use may override usual contraindications. Review renal, hepatic and cardiac disease, diabetes, infection and psychiatric history. Counsel about urgent mood, psychotic or suicidal symptoms. Check CYP3A inhibitors/inducers, including ritonavir, cobicistat and azoles; NSAIDs increase gastrointestinal risk, anticoagulation may need closer monitoring and glucose-lowering treatment may need adjustment. Pregnancy and breastfeeding require individual benefit–risk assessment. Use a suitable lower formulation for tapering rather than splitting this tablet or solution.
06Complications, monitoring and follow-upAdverse effects, response and longer-term review.
- At each oncology review, record performance, pain, neurological function, weight, organ symptoms, treatment toxicity and the patient’s current goals before interpreting scan measurements.
- Use CECT or FDG PET-CT that demonstrates response and consider retaining the initial effective modality; do not use bone scintigraphy to monitor bone response.
- For bone-targeted treatment, monitor renal function, calcium and dental risk according to the selected medicine and act early on new focal pain or fracture risk.
- For uncontrolled local disease, track bleeding, exudate, odour, infection, analgesic effect and dressing burden and provide a rapid contact route for deterioration.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Biopsy can reopen options
Recurrent disease may differ from the primary; a current receptor result can create or remove endocrine and HER2 treatment pathways.
Visceral metastasis is not always crisis
Liver or lung involvement alone does not mandate chemotherapy; imminent organ threat and the need for rapid relief define the urgency.
Bone scans do not monitor response well
Healing sclerosis and flare can confuse scintigraphy, so NICE directs response monitoring toward an effective CT or PET-CT modality.
Palliative care is concurrent care
Symptom specialists improve comfort, planning and family support while disease-modifying treatment continues; referral does not mean oncology has stopped.
08Common pitfallsFrequent interpretation and management errors.
- 01
Assuming every new lesion is breast-cancer recurrence without biopsy when safe can miss a second primary or a changed receptor phenotype.
- 02
Waiting for paralysis before activating the MSCC pathway sacrifices the opportunity to preserve gait, sphincter function and independence.
- 03
Using chemotherapy automatically for every ER-positive visceral metastasis ignores endocrine-sensitive disease without imminent organ threat.
- 04
Reserving wound and palliative teams for the last days leaves pain, exudate, bleeding, odour and caregiver distress poorly controlled.